Fidelity® Select Pharmaceuticals Port (FPHAX)

23.34 +0.12  +0.52% Dec 6 USD
View Full Chart
Total Returns Chart

Key Stats

Net Asset Value 23.34
Turnover Ratio 55.00%
1 Year Fund Level Flows -91.22M

Performance & Returns

  Total Return Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 5.95% 9.26% 88
3M 10.35% 12.53% 69
6M 17.23% 14.26% 22
YTD 24.39% 22.87% 38
1Y 16.77% 12.45% 25
3Y 13.68% 14.47% 62
5Y 5.24% 7.96% 77
10Y 13.48% 14.88% 71
15Y 11.39% 11.07% 45
20Y -- 10.28% --
As of Dec. 6, 2019. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.59% 0.59% 0.00%
Stock 99.13% 99.13% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.28% 0.28% 0.00%
As of Oct. 31, 2019

Region Exposure

Americas 59.71%
North America 59.71%
Latin America 0.00%
Greater Europe 37.81%
United Kingdom 14.64%
Europe Developed 23.18%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 2.48%
Japan 2.32%
Australasia 0.00%
Asia Developed 0.17%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.27%
As of Oct. 31, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Oct. 31, 2019

Stock Market Capitalization

Giant 61.45%
Large 21.31%
Medium 10.75%
Small 5.66%
Micro 0.83%
As of Oct. 31, 2019

Stock Style Exposure

Large Cap Value 23.87%
Large Cap Blend 30.93%
Large Cap Growth 29.75%
Mid Cap Value 2.33%
Mid Cap Blend 2.07%
Mid Cap Growth 4.86%
Small Cap Value 0.11%
Small Cap Blend 1.50%
Small Cap Growth 4.58%
As of Oct. 31, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
AZN AstraZeneca PLC ADR 12.54% 47.68 +0.13%
BMY Bristol-Myers Squibb Company 10.40% 59.95 +0.79%
JNJ Johnson & Johnson 10.13% 140.38 +0.59%
SNY Sanofi SA ADR 8.44% 46.03 -0.11%
ROG Roche Holding AG Dividend Right Cert. 7.45% -- --
LLY Eli Lilly and Co 5.08% 119.64 -0.11%
MRK Merck & Co Inc 4.58% 88.85 +0.11%
NVS Novartis AG ADR 4.44% 92.07 +0.47%
ZTS Zoetis Inc Class A 3.91% 121.72 +1.34%
AGN Allergan PLC 2.79% 186.37 +0.16%
As of Oct. 31, 2019
Advertisement

Basic Info

Investment Strategy
The investment seeks capital appreciation. The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol FPHAX
Equity Style Large Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name Fidelity Investments
Reports
One Page Report Download

Manager Info

Name Tenure
Karim Suwwan de Felipe 2.34 yrs

Net Fund Flows

1M 7.220M
3M -6.422M
6M -35.82M
YTD -91.27M
1Y -91.22M
3Y -651.71M
5Y -1.079B
10Y -424.67M
As of Nov. 30, 2019

Risk Info

Beta (5Y) 0.8464
Historical Sharpe Ratio (10Y) 1.024
Historical Sortino (All) 0.6706
Daily Value at Risk (VaR) 1% (All) 2.87%
Monthly Value at Risk (VaR) 1% (All) 11.70%

Fundamentals

Dividend Yield TTM (12-6-19) 1.27%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 25.20
Weighted Average Price to Sales Ratio 4.314
Weighted Average Price to Book Ratio 4.256
Weighted Median ROE 23.42%
Weighted Median ROA 5.23%
Forecasted Dividend Yield 2.28%
Forecasted PE Ratio 17.40
Forecasted Price to Sales Ratio 4.049
Forecasted Price to Book Ratio 3.355
Number of Holdings 63
As of Oct. 31, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 8.45%
Forecasted Book Value Growth 0.17%
Forecasted Cash Flow Growth 4.08%
Forecasted Earnings Growth 24.50%
Forecasted Revenue Growth 4.44%
As of Oct. 31, 2019

Comparables

Edit

Attributes

Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment 0.00 USD
Minimum Subsequent Investment 0.00 USD
Fees
Actual 12B-1 Fee --
Actual Management Fee 0.54%
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
Key Dates
Inception Date 6/18/2001
Termination Date
Last Annual Report Date 2/28/2019
Last Prospectus Date 4/29/2019
Attributes
Exchange Traded Share No
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.